Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Beclomethasone Dipropionate Suppositories in Healthy Volunteers
NCT04873063Phase 1Completed
- Sponsor
- SOFAR
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of beclomethasone dipropionate in ulcerative proctosigmoiditis (2 arms), sponsored by SOFAR. Primary endpoints: Maximum Plasma Concentration (Morning) at Day 7, Maximum Plasma Concentration (Evening) at Day 7 and 7 more. Started Oct 2021; status: completed.
02
Drugs
beclomethasone dipropionate
03
Conditions
ulcerative proctosigmoiditis
Beyond the preview
Go deeper on NCT04873063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873063.